(Q35771498)

10 August 2017

1 reference

title

Palonosetron. (English)

1 reference

10 August 2017

2

Lesley J Scott

1 reference

10 August 2017

M Asif A Siddiqui

1

1 reference

10 August 2017

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

64

1 reference

10 August 2017

issue

10

1 reference

10 August 2017

page(s)

1125-32; discussion 1133-4

1 reference

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

10 August 2017

cites work

1 reference

12 December 2020

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

1 reference

12 December 2020

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

1 reference

12 December 2020

Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study

1 reference

12 December 2020

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery

1 reference

12 December 2020

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

1 reference

12 December 2020

Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo

1 reference

12 December 2020

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

1 reference

12 December 2020

Guidelines for anti-emetic therapy: acute emesis

1 reference

12 December 2020

Nausea and vomiting as major complications of cancer chemotherapy.

1 reference

12 December 2020

The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro

1 reference

12 December 2020

Drug treatment of chemotherapy-induced delayed emesis

1 reference

12 December 2020

10.2165/00003495-200464100-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1037955349

0 references

1 reference